<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964807</url>
  </required_header>
  <id_info>
    <org_study_id>P0052956</org_study_id>
    <secondary_id>P50CA180890</secondary_id>
    <nct_id>NCT01964807</nct_id>
  </id_info>
  <brief_title>Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products</brief_title>
  <official_title>Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers
      that can detect differences in the cardiovascular safety of various tobacco products, whether
      conventional, new or emerging, in order to help the FDA with the task of regulating them.
      This will be achieved through 4 aims:

      Aim 1: Determine the relative contributions of nicotine and combustion products to the
      cardiovascular risk of active cigarette smoking.

      Aim 2: Determine which cardiovascular risk biomarkers are affected by exposure to secondhand
      smoke.

      Aim 3: Determine the cardiovascular risk of smokeless tobacco use. Aim 4: Determine the
      cardiovascular risk of electronic cigarettes and the respective contributions of nicotine and
      electronic cigarette vapor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking is a major cause of cardiovascular disease (CVD).1 In contrast, the
      cardiovascular risks of other popular tobacco products (smokeless tobacco), new tobacco
      products ( e-cigarettes) and proposed products (reduced nicotine cigarettes) are not
      adequately understood. The FDA will need information about the cardiovascular safety of these
      products to inform their regulatory decisions. While long-term clinical outcome studies of
      the cardiovascular risks of these tobacco products would be optimal, they take too long to
      provide the data that the FDA needs now. Disturbances in the function of vascular endothelium
      (the lining of arteries, which plays an important role in regulating vascular function) and
      the activation of the autonomic nervous system, as well as increased inflammation, oxidative
      stress and propensity to thrombosis (clotting), are key mechanisms in the progression of CVD
      and validated biomarkers of CVD risk. These biomarkers form the basis for our model to assess
      the CVD risks of tobacco product use and secondhand smoke exposure. We will conduct
      controlled, short-term exposures of human subjects to test products that provide a wide range
      of nicotine, particle, and other cardiovascular toxin concentrations to determine how these
      components associated with tobacco use adversely affect cardiovascular risk.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the brachial artery</measure>
    <time_frame>up to 3 hours after use of tobacco product</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>up to 3 hours after use of product.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clot strength and plasma levels of IL-6 and 8-isoprostane</measure>
    <time_frame>up to 3 hours after use of product.</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Adverse Effect of Other Agents Primarily Affecting the Cardiovascular System, Initial Encounter</condition>
  <arm_group>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will smoke 1 cigarette, NIDA test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with &lt;0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonsmokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e-cigarette users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarette, NIDA test type with 16.6 mg nicotine</intervention_name>
    <description>Smoke a single cigarette for up to 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <other_name>Cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarette, NIDA test type with &lt;0.45 mg nicotine</intervention_name>
    <description>Smoke a single low-nicotine cigarette for up to 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <other_name>Cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic cigarette with 18 mg/ml nicotine</intervention_name>
    <description>Use electronic cigarette with 18 mg/ml nicotine for 30 minutes</description>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Cigarette with no nicotine</intervention_name>
    <description>Use electronic cigarette with no nicotine for 30 minutes</description>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moist snuff</intervention_name>
    <description>Use moist snuff for 30 minutes</description>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <other_name>commercially available moist oral snuff</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham smoking</intervention_name>
    <description>Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Secondhand cigarette smoke (SHS)</intervention_name>
    <description>180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes</description>
    <arm_group_label>Nonsmokers</arm_group_label>
    <other_name>environmental tobacco smoke</other_name>
    <other_name>ETS</other_name>
    <other_name>SHS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conditioned, filtered air</intervention_name>
    <description>Exposure to conditioned, filtered air for 180 minutes</description>
    <arm_group_label>Nonsmokers</arm_group_label>
    <other_name>Clean, filtered, temperature and humidity controlled air</other_name>
    <other_name>Negative control for SHS exposure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham moist snuff</intervention_name>
    <description>Chew gum for 30 minutes</description>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <other_name>Chewing gum</other_name>
    <other_name>Negative control for moist oral snuff use</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Groups: Age 18-50

          -  Can tolerate withholding their medications for two weeks at a time

          -  Group 1: Active smokers

          -  Group 2: Nonsmokers

          -  Group 3: Active users of smokeless tobacco

          -  Group 4: Active users of electronic cigarettes

          -  Additional Inclusion Criteria for E-Cigarette Users:

          -  Currently use ofe-cigarettes &gt; 5 times a day

          -  Has used e-cigarettes for &gt;3 months

          -  Additional Inclusion Criteria for Active Smokers: Currently smoke &gt;5 cigarettes per
             day ≥ 1 pack year

        Exclusion Criteria:

          -  Exclusion Criteria for all subjects

          -  Physician diagnosis of:

          -  asthma

          -  heart disease

          -  hypertension

          -  dyslipidemia

          -  thyroid disease

          -  diabetes

          -  renal or liver impairment

          -  glaucoma.

          -  Unstable psychiatric condition (such as current major depression, history of
             schizophrenia or bipolar disorder)

          -  current use of more than two psychiatric medications

          -  Pregnancy or breastfeeding (by history)

          -  Alcohol, opiate, cocaine, amphetamine or methamphetamine dependence within the past 5
             years

          -  BMI &gt; 35 and &lt; 18

          -  Current opiate, cocaine, amphetamine or methamphetamine use (by history or urine test)

          -  Occupational exposure to smoke, dusts and fumes

          -  Concurrent participation in another clinical trial

          -  Unable to communicate in English

          -  Additional Exclusion Criteria for Active Smokers:

          -  Unable to hold marijuana for 1 week prior to each study visit.

          -  Exhaled CO &lt;10 ppm at each visit

          -  Negative salivary cotinine test using a rapid-read, over the counter test with 30
             ng/ml cutoff

          -  Additional Exclusion Criteria for Nonsmokers:

          -  More than 1 pack year smoking history

          -  Quit smoking &lt; 5 years ago

          -  Ever a daily marijuana smoker

          -  Smoked anything within the last 3 months

          -  Additional Inclusion Criteria for Smokeless Tobacco Users:

          -  Use of moist oral snuff &gt; 5 times a day

          -  Has used moist oral snuff for at least 0.5 years

          -  Additional Exclusion Criteria for Smokeless Tobacco Users:

          -  Current smoker

          -  Quit smoking &lt; 0.5 years ago

          -  Additional Exclusion Criteria for E-Cigarette Users:

          -  Current use of other tobacco products

          -  Unable to hold marijuana for 1 week prior to each study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ganz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzaynn F Schick, PhD</last_name>
    <phone>415-206-5904</phone>
    <email>suzaynn.schick@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzaynn F. Schick, PhD</last_name>
      <phone>415-206-5904</phone>
      <email>sschick@medsfgh.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Ganz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzaynn F. Schick, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular</keyword>
  <keyword>tobacco</keyword>
  <keyword>cigarettes</keyword>
  <keyword>secondhand cigarette smoke</keyword>
  <keyword>SHS</keyword>
  <keyword>smokeless tobacco</keyword>
  <keyword>chewing tobacco</keyword>
  <keyword>snus</keyword>
  <keyword>electronic cigarettes</keyword>
  <keyword>vapor</keyword>
  <keyword>particles</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>flow-mediated dilation</keyword>
  <keyword>FMD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

